PAVmed Inc. 2025 Annual Report: Key Investor Insights

Summary of the Annual Report

PAVmed Inc. has released its annual report for the fiscal year ended December 31, 2025. The report, filed as a Form 10-K with the SEC, details the company’s business operations, financial condition, and key risks. Below is a detailed breakdown of the most important and potentially share price-sensitive information for investors and shareholders.

Key Points for Investors

• Form 10-K Filed: The company filed its annual report pursuant to Section 13 of the Securities Exchange Act of 1934, confirming its compliance and providing a comprehensive overview of its operations.
• Company Status: PAVmed Inc. is listed as a non-accelerated filer and a smaller reporting company, which means it may have less stringent reporting requirements and potentially smaller market capitalization.
• Common Stock Details: The company’s common stock, \$0.001 par value per share, trades on The NASDAQ Stock Market LLC under the symbol PAVM.
• Shares Outstanding: As of December 31, 2025, there were 995,673 shares of common stock outstanding. By March 27, 2026, this number increased significantly to 6,383,089 shares, including shares underlying unvested restricted stock awards. This dramatic increase is highly price-sensitive, as it may indicate dilution and affect share value.
• Preferred Stock Activity:
  • Series B Preferred Stock: 1,529,389 shares issued and outstanding as of December 31, 2025 (up from 1,412,865 in 2024).
  • Series C Preferred Stock: 19,457 shares issued and outstanding as of December 31, 2025 (none in 2024).
  • Par Value: Both Series B and Series C preferred stocks have a par value of \$0.001 per share, but Series C preferred stock has a stated value of \$1,080 per share, which is a material detail for valuation.
• Reverse Stock Split: The company executed a 1-for-30 reverse stock split, which is a significant corporate action that can affect share price, investor perception, and market capitalization.
• SEC Compliance:
  • PAVmed confirms it is not a shell company and has maintained reporting compliance, including electronic submission of Interactive Data Files.
  • No corrections or restatements of financial statements are reported, and there is no requirement for a recovery analysis of incentive-based compensation.
  • The company did not receive an auditor attestation for its internal controls over financial reporting.
• Risk Factors: The report contains forward-looking statements and explicitly highlights substantial risks and uncertainties, including business strategy, financial position, and future operations. Investors are cautioned that actual results may differ significantly from those projected.
• Market Value: As of June 30, 2025, the aggregate market value of the registrant’s voting stock held by non-affiliates is disclosed, which is crucial for shareholders to gauge market capitalization and liquidity.
• Corporate Governance & Financial Disclosure: The report includes detailed sections on executive compensation, director independence, principal accountant fees, and management’s discussion and analysis of financial condition and results of operations.
• Proxy Statement: Portions of the company’s definitive proxy statement for its 2026 annual meeting of stockholders are incorporated by reference, to be filed within 120 days after year-end.

Potential Share Price Sensitive Issues

• Significant Share Increase: The increase in common shares outstanding from 995,673 to 6,383,089 in a short period is material and may signal dilution, which can negatively impact share price.
• Reverse Stock Split: The 1-for-30 reverse stock split is a major event, typically aimed at raising share price and maintaining NASDAQ listing requirements, but can also lead to reduced liquidity and negative investor sentiment.
• Preferred Stock Issuance: New issuances of Series C Preferred Stock and increased Series B Preferred Stock may affect the capital structure and future earnings per share calculations, especially as convertible preferred stocks are “potentially participating securities” under the two-class method.
• Risk Disclosures: Explicit caution about forward-looking statements and substantial uncertainties may affect investor expectations and share price volatility.

Important Notices for Shareholders

• No Auditor Attestation: There was no auditor attestation on internal controls, which may concern some investors about the robustness of financial reporting.
• No Financial Statement Corrections: No restatements or corrections reported, which is positive for investor confidence.
• Non-Accelerated Filer & Smaller Reporting Company: These designations may affect the frequency and depth of disclosures, and signal a smaller company profile.
• Proxy Statement Filing: Proxy statement will be filed within 120 days, which may contain additional material information for shareholders.

Disclaimer

This article is based on the PAVmed Inc. 2025 Annual Report (Form 10-K) and is intended for informational purposes only. It does not constitute investment advice or a recommendation to buy or sell securities. Investors should consult the full SEC filings and their financial advisors before making investment decisions. The company’s forward-looking statements are subject to risks and uncertainties. Actual results may differ materially from those described herein.

View PAVmed Inc. Historical chart here